辽宁
参考资料
[1] ClinicalTrials.gov. NCT07764237.
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults.
[2] ClinicalTrials.gov. NCT05743881.
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to 24 Months.
[3] Moderna. Review of Investigational RSV (mRNA-1345) and RSV/hMPV (mRNA-1365) Vaccines in Infants and Children <2 Years. FDA VRBPAC, Dec 12, 2024.
[4] FDA. Considerations for Respiratory Syncytial Virus Vaccine Safety in Pediatric Populations. VRBPAC Briefing Document, Dec 12, 2024.
[5] August A, et al. Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults. 2022.
[6] Schnyder Ghamloush S, et al. Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children. Pediatrics. 2024.
欢迎来到医食参考新媒体矩阵
2023年疫苗接种攻略
阳过了，该怎么打疫苗？最全接种指导手册来了
来源| RNAScript
校稿| Alice编审| Hide / Blue sea
编辑 设计| Leon
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
